AELMHU has published a new report on access to orphan drugs in Spain. This edition is a four-monthly report that mainly reflects what has happened in access to this type of treatment during the first four months of the year.
Taking into account this period, the report reflects that during this time there are new orphan drugs with trade names, new marketing authorisations, 4 new national codes and 2 new products financed by the National Health System.
With these data, we find that as of 30 April 2022, there are 181 orphan medicinal products with a trade name, 132 with marketing authorisation, 113 with a National Code and 58 products financed by the NHS.
To date, of the 113 orphan drugs that have arrived in Spain, 55 are still awaiting a positive price and funding decision, of which 49% have been waiting for 3 or more years.
For this report, the association has used only public sources from the European Union and the Ministry of Health, updating the information on a four-monthly basis twice a year and once a year.
The infographic of the quarterly report is available here.
